# Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

> **NCT01723202** · PHASE2 · COMPLETED · sponsor: **Bhavana Konda** · enrollment: 53 (actual)

## Conditions studied

- Follicular Thyroid Cancer
- Insular Thyroid Cancer
- Papillary Thyroid Cancer
- Recurrent Thyroid Cancer

## Interventions

- **DRUG:** dabrafenib
- **DRUG:** trametinib

## Key facts

- **NCT ID:** NCT01723202
- **Lead sponsor:** Bhavana Konda
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-07
- **Primary completion:** 2022-04-15
- **Final completion:** 2022-04-15
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723202, "Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01723202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*